Xencor Inc (NASDAQ: XNCR) is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics. The filing excerpts provided do not contain sufficient detail to describe Xencor's revenue model, product pipeline, partnership structure, financial results, or competitive position beyond the company's basic identity as a registrant filing a 10-K for the fiscal year ended as reported in the accession 000132673226000015 filed 2026-02-25. Because the supplied excerpts consist only of boilerplate SEC cover-page language and do not include the body of the annual report, specific claims about revenue streams, collaboration agreements, approved products, clinical programs, headcount, cash position, or named competitors cannot be supported and are omitted per source-grounding requirements.

Source: SEC 10-K, filed 2026-02-25

Industry: Pharmaceutical Preparations Peers: Agios Pharmaceuticals Inc BridgeBio Pharma Inc Day One Biopharmaceuticals, Inc. Travere Therapeutics Inc Iovance Biotherapeutics Inc Ligand Pharmaceuticals Inc Myriad Genetics Inc Novavax Inc Vaxcyte Inc